Addition of Elotuzumab Prolongs Survival in Relapsed or Refractory Myeloma
Treatment with elotuzumab plus lenalidomide and dexamethasone (ERd) was associated with significant and clinically meaningful reductions in mortality risk, compared with lenalidomide and dexamethasone...
“Off-the-Shelf” CAR T-Cell Therapy for Myeloma Receives Fast Track Designation
The FDA has granted fast track designation to PBCAR269A, an allogeneic CAR T-cell therapy for the treatment of patients with relapsed or refractory MM...
FDA Grants Priority Review to Melflufen for Myeloma
The FDA granted priority review to a new drug application for INN melphalan flufenamide, or melflufen, in combination with dexamethasone for the treatment of...
Idecabtagene Vicleucel Granted Priority Review for Myeloma
The FDA has granted priority review to the biologics license application of idecabtagene vicleucel (ide-cel), for the treatment of adult patients with MM who...
FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin-blmf, an anti–B-cell maturation antigen (BCMA) antibody-drug conjugate therapy, received accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma...
Phase I Trial Supports CC-92480 for Heavily Pretreated Myeloma
Results from a first-in-human trial of CC-92480 in patients with relapsed or refractory multiple myeloma show a manageable safety profile and promising efficacy, according...
Isatuximab Plus Carfilzomib: A New Standard for Relapsed/Refractory Myeloma?
The three-drug combination of the CD38-targeting antibody isatuximab plus carfilzomib and dexamethasone significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple...
Idecabtagene Vicleucel Demonstrates Deep, Durable Responses in Relapsed/Refractory Myeloma
The BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (previously known as bb2121) induced responses in nearly three-quarters of patients with relapsed/refractory multiple...
DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma
Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
Study Supports Use of AHCT Over VMP as Intensification in Newly Diagnosed Myeloma
In patients with newly diagnosed myeloma, following induction chemotherapy, early autologous hematopoietic cell transplantation (AHCT) as intensification therapy prolonged progression-free survival (PFS), compared with...
Current Issue
November 2020 Bonus ASH Annual Meeting Preview Edition (Volume 6, Issue...
View issue flipbook
November 2020 Bonus ASH Annual Meeting Preview Edition
Volume 6, Issue 14This issue offers a behind-the-scenes look at this year's virtual annual meeting,...